Business
Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call
Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”
About this update from Vivos Therapeutics, Inc.
[{"type":"text","content":"Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET\nHIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2021 after market close today, Thursday, March 31, 2022. The Company will conduct a conference call today at 5:00 pm (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and growth strategy. To access the conference call, please dial (888) 256-1007, or for international callers, (720) 543-0214. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 5532262. The replay will be available until April 14, 2022. A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available on the Company’s website for 30 days following the call. About Vivos Therapeutics, Inc. Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment methods for treating patients with dentofacial abnormalities and / or mild to moderate sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution. The Vivos Method has proven to be effective in approximately 25,000 patients treated worldwide by more than 1,450 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore p...